MX2022000899A - Stable pharmaceutical compositions with enhanced solubility comprising the combination of a cox-2 inhibitor and an anthraquinone derivative. - Google Patents

Stable pharmaceutical compositions with enhanced solubility comprising the combination of a cox-2 inhibitor and an anthraquinone derivative.

Info

Publication number
MX2022000899A
MX2022000899A MX2022000899A MX2022000899A MX2022000899A MX 2022000899 A MX2022000899 A MX 2022000899A MX 2022000899 A MX2022000899 A MX 2022000899A MX 2022000899 A MX2022000899 A MX 2022000899A MX 2022000899 A MX2022000899 A MX 2022000899A
Authority
MX
Mexico
Prior art keywords
cox
inhibitor
anthraquinone derivative
combination
pharmaceutical compositions
Prior art date
Application number
MX2022000899A
Other languages
Spanish (es)
Inventor
Rivera Reyna Astrid Salto
Rodríguez Jesús Anzures
CHAVEZ Jorge OROZCO
Original Assignee
Laboratorios Liomont S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Liomont S A De C V filed Critical Laboratorios Liomont S A De C V
Priority to MX2022000899A priority Critical patent/MX2022000899A/en
Publication of MX2022000899A publication Critical patent/MX2022000899A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition containing a COX-2 inhibitor and an anthraquinone derivative, designed for a single-dose administration. Also, it aims to improve the solubility of the active ingredients without affecting their stability or compatibility between them and the other components. Further, said composition is useful for treating the pain and inflammation of osteoarthritis, rheumatoid arthritis, degenerative joint disease, and related diseases.
MX2022000899A 2022-01-21 2022-01-21 Stable pharmaceutical compositions with enhanced solubility comprising the combination of a cox-2 inhibitor and an anthraquinone derivative. MX2022000899A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2022000899A MX2022000899A (en) 2022-01-21 2022-01-21 Stable pharmaceutical compositions with enhanced solubility comprising the combination of a cox-2 inhibitor and an anthraquinone derivative.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2022000899A MX2022000899A (en) 2022-01-21 2022-01-21 Stable pharmaceutical compositions with enhanced solubility comprising the combination of a cox-2 inhibitor and an anthraquinone derivative.

Publications (1)

Publication Number Publication Date
MX2022000899A true MX2022000899A (en) 2022-06-20

Family

ID=87929482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000899A MX2022000899A (en) 2022-01-21 2022-01-21 Stable pharmaceutical compositions with enhanced solubility comprising the combination of a cox-2 inhibitor and an anthraquinone derivative.

Country Status (1)

Country Link
MX (1) MX2022000899A (en)

Similar Documents

Publication Publication Date Title
IL156361A0 (en) Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
BR0209320A (en) pharmaceutically active uridine esters
JP6469843B2 (en) Cineol-containing composition for nasal application
EA200200806A1 (en) PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN AGENTISTS PROSTAGLANDINA
ES2137138A1 (en) Pyrazoline derivatives, their preparation and application as medicaments
EP3068373B1 (en) Aqueous based capsaicinoid formulations and methods of manufacture and use
HK1084015A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2-
GB2394419A (en) Joint lubrication with p2y purinergic receptor agonists
CS261637B1 (en) Antihepatotoxic pharmaceutical preparat
AU2013341380A2 (en) Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid
CA2507926A1 (en) Pharmaceutical composition comprising chito-oligomers
KR102398013B1 (en) Compositions useful for preventing and/or treating osteoarthritis and pain and cartilage damage
KR20070003995A (en) Compositions with reduced hepatotoxicity
MX2022016263A (en) Cyclobutyl-urea derivatives.
MX2022000899A (en) Stable pharmaceutical compositions with enhanced solubility comprising the combination of a cox-2 inhibitor and an anthraquinone derivative.
US8367636B2 (en) Composition based on salts of hyaluronic acid for treating epithelial lesions
MX2022006130A (en) Injectable compositions of ursodeoxycholic acid.
RU2008126108A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS CONTAINING CLODRONIC ACID AND HYALURONIC ACID
EP2162491A1 (en) Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation
MX2023001572A (en) Solid dosage forms of palbociclib.
WO2020044114A3 (en) Methotrexate pharmaceutical composition
MX2022011961A (en) Composition having improved voluntary acceptance.
JP3969587B2 (en) Azulene sulfonate sodium preparation
MX2018011142A (en) A synergistic pharmaceutical combination of a selective cyclloxygenasa-2 inhibitor and an antraquinone derivative.
GB2355930A (en) Injection of pantothenic acid for relief of pain in joints